This inventor holds 4 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Seven Bridges Genomics, Inc.. Active years: 2015-2019.
Location History:
- Cambridge, MA (US) (2018)
- Somerville, MA (US) (2015 - 2019)
Company Filing History:
Years Active: 2015-2019
Title: Nathan Meyvis: Innovator in Transcriptome Analysis
Introduction
Nathan Meyvis is a prominent inventor based in Somerville, MA, known for his contributions to the field of transcriptome analysis. With a total of four patents to his name, he has made significant advancements in the methods and systems used for analyzing RNA sequences.
Latest Patents
Meyvis's latest patents include innovative systems and methods for transcriptome analysis. One of his notable inventions provides systems and methods for analyzing RNA-Seq reads, where an annotated reference is represented as a directed acyclic graph (DAG). This invention allows for the representation of features such as exons and introns as nodes in the DAG, linked by edges in their canonical genomic order. The DAG is scalable and can be populated by importing from an extrinsic annotated reference. Another significant patent involves methods of analyzing a transcriptome using paired-end data in a directed acyclic structure. This method includes obtaining paired-end reads, finding optimal alignments, and identifying candidate paths to determine the best scoring alignment.
Career Highlights
Nathan Meyvis currently works at Seven Bridges Genomics, Inc., where he continues to develop innovative solutions in genomics. His work focuses on enhancing the analysis of transcriptomic data, which is crucial for understanding gene expression and its implications in various biological processes.
Collaborations
Meyvis collaborates with Deniz Kural, contributing to the advancement of genomic research and the development of new analytical methods.
Conclusion
Nathan Meyvis is a key figure in the field of transcriptome analysis, with a strong portfolio of patents that reflect his innovative spirit and dedication to advancing genomic research. His work at Seven Bridges Genomics, Inc. continues to impact the scientific community positively.